Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is among the most promising biotech stocks to buy according to hedge funds. According to a recent disclosure with the SEC, Assenagon Asset Management S.A. lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by a whopping 439.0% during the second quarter. Following the acquisition of 947,865 shares, the firm now owns 1,163,755 shares of the company’s stock, reflecting an investment worth $42,314,000 and ownership of about 1.23%.

During the latest earnings call, management highlighted the company’s history of accelerating programs through approval in several areas. While reporting Breakthrough Therapy designation for GTX-102 in Angelman syndrome, Ultragenyx Pharmaceutical Inc. appears to be in a good position to advance UX143, which will be a transformational treatment for pediatric and adult patients with osteogenesis imperfecta.

Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light

 On September 26, 2025, Regeneron Pharmaceuticals announced the FDA approval of a label expansion for its anti-cholesterol agent Evkeeza, which is offered globally, in collaboration with Ultragenyx Pharmaceutical Inc.. This, along with other strategic collaborations, hints at a positive outlook for the company.

Ultragenyx Pharmaceutical Inc. is a California-based biopharmaceutical company that discovers, develops, and commercializes novel products for treating rare and ultra-rare genetic diseases. The core offerings of the company include Crysvita (burosumab), Mepsevii, Dojolvi, and Evkeeza (evinacumab).

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.